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Abstract 1 
 2 
Background: The standard of care for primary central nervous system lymphoma 3 
(PCNSL) is systemic chemotherapy plus/minus whole brain radiotherapy or 4 
intrathecal therapy. In contrast to other brain tumors, efforts at resection are 5 
discouraged.  6 
Methods: This is a secondary analysis of the G-PCNSL-SG-1 trial, a large 7 
randomized phase III study comprising 526 patients with PCNSL. 8 
Results: Progression-free survival (hazard ratio (HR): 1.39, 95% CI 1.10-1.74, 9 
p=0.005) and overall survival (HR: 1.33, 95% CI 1.04-1.70, p=0.024) were 10 
significantly shorter in biopsied patients compared with patients with subtotal or gross 11 
total resections. This difference in outcome was not due to differences in age or 12 
performance score. When controlled for the number of lesions, the HR of biopsy 13 
versus subtotal or gross total resection remained unchanged for PFS (HR=1.37, 14 
p=0.009), but was smaller for OS (HR=1.27, p=0.085). 15 
Conclusions: This analysis of the largest PCNSL trial ever performed challenges the 16 
traditional view that the extent of resection has no prognostic impact in this disease. 17 
Therefore, we propose to reconsider the statement that efforts at resection should be 18 
discouraged at least if resection seems safe, e.g., often in patients with single 19 
PCNSL lesions. 20 
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Introduction 1 
 2 
PCNSL is a rare brain tumor with an annual incidence in the range of 0.5/100,000 3 
(www.cbtrus.org). All treatment modalities except high-dose methotrexate (HD-MTX) 4 
have remained controversial, notably whole brain radiotherapy (WBRT) and 5 
intrathecal chemotherapy. Yet, a consistent recommendation of virtually all review 6 
articles and national or international guidelines, including the National 7 
Comprehensive Cancer Network (NCCN) guidelines, states that efforts at resection 8 
of PCNSL should not be undertaken. However, this recommendation is not based on 9 
contemporary reports. In 1974, Henry and colleagues1 reported a survival of 3.3 10 
months in 15 patients managed with supportive care alone, 4.6 months in 28 patients 11 
after surgery alone, but 15.2 months in 21 patients treated with radiotherapy, with or 12 
without surgery. De Angelis and colleagues2 observed no complications in 19 13 
patients with stereotactic biopsies whereas 4 of 10 patients who had a complete 14 
resection suffered a severe postoperative deficit, indicating an increased surgical risk 15 
in this patient population. One of the most influential articles represents a 16 
retrospective analysis of 248 patients treated between 1980 and 1995 published in 17 
2000: the survival rates at 1 year were 56.6% for completely resected patients, 18 
31.8% for partially resected patients, and 48.6% for biopsied patients.3 Another, more 19 
recent retrospective study of 32 patients also questioned the value of surgical 20 
resection although the authors essentially acknowledged that their study was 21 
inconclusive.4 The G-PCNSL-SG-1 trial which examined the role of WBRT in the 22 
treatment of newly diagnosed PCNSL patients eligible for HD-MTX-based 23 
chemotherapy provides a unique data base to confirm or refute this statement on the 24 
lack of impact of surgery in PCNSL.5 25 
26 
Methods 1 
 2 
This was an unplanned secondary analysis of the G-PCNSL-SG-1 trial for an 3 
association of the type of surgery and extent of resection as documented at study 4 
entry and the clinical outcome parameters response, CR rate at 6 months, PFS and 5 
OS. Open and stereotactic biopsies were pooled. CR rate at 6 months, PFS and OS 6 
were analyzed using the Kaplan Meier Method and the log rank test. With 315 (OS) 7 
and 414 (PFS) events, hazard ratios > 1.44 (OS) and > 1.37 (PFS) could be detected 8 
(type 1 error 0.05, two-sided, type 2 error 0.8) in the Cox regression model between 9 
patients with subtotal or gross total resection (pooled) and patients with biopsy. 10 
Populations are defined as follows5: 526 patients were eligible for study entry and 11 
entered the first study phase of HD-MTX-based chemotherapy (non-randomized), 12 
411 patients completed the first and entered the second phase of the trial where 13 
randomization (WBRT versus no WBRT) should have become effective (intention to 14 
treat-population, ITT), and 318 patients were treated as randomized (per protocol 15 
population, PP). 16 
 17 
 18 
19 
Results 1 
 2 
Of the 526 patients of the primary eligibility population, 67 patients had a gross total 3 
resection, 70 patients had a subtotal resection, and 379 had a biopsy, 48 open and 4 
331 stereotactic. Gross total resection in patients with more than one lesion required 5 
gross total removal of all lesions. No data for type of surgery were provided for 10 6 
patients. There was no difference in the three groups regarding age or KPS which 7 
was determined at study entry, that is, after surgery (Table). There was also no such 8 
difference for age or KPS when gross total and subtotal resections were pooled and 9 
compared with the biopsied population (data not shown). Biopsied patients had more 10 
often multiple lesions than resected patients (p=0.003). 11 
The complete remission rate at 6 months was 56.7% for gross totally resected, 12 
41.4% for subtotally resected, and 34.3% for biopsied patients (p=0.001). Of note, we 13 
do not attribute the increase in the complete remission rate at 6 months to surgery 14 
alone even after gross total resection since PCNSL is a very aggressive lymphoma 15 
expected to recur within 6 months even after gross total resection without adequate 16 
chemotherapy or chemoradiotherapy. 17 
There was no difference for PFS or OS between patients with a gross total versus 18 
subtotal resection. However, biopsied patients had inferior PFS and OS compared 19 
with gross totally resected patients or gross totally and subtotally resected patients 20 
pooled (Table, Figure). When biopsied patients were compared with subtotally or 21 
gross totally resected patients, the hazard ratios for PFS were 1.39 (95% CI 1.10-22 
1.74, p=0.005) for all 526 patients, 1.34 (95% CI 1.00-1.79, p=0.047) for the PP 23 
population, 1.57 (95% CI 0.80-3.08, p=0.186) for the ITT-minus-PP population, and 24 
1.09 (95% CI 0.68-1.74, p=0.73) for patients not entered into the ITT population. The 25 
hazard ratios for OS were 1.33 (95% CI 1.04-1.70, p=0.024) for all 526 patients, 1.30 26 
(95% CI 0.94-1.79, p=0.116) for the PP population, 1.33 (95% CI 0.62-2.85, p=0.46) 1 
for the ITT-minus-PP population, and 1.04 (95% CI 0.65-1.65, p=0.88) for patients 2 
not entered into the ITT population. 3 
In a sensitivity analysis of the primary eligibility population of 526 patients, we 4 
investigated whether the number of lesions was a confounder, i.e., whether patients 5 
with a larger number of lesions with presumed worse prognosis underwent surgery 6 
less frequently. To this aim, we subdivided our sample into patients with one lesion 7 
(60.8%, n=262) and those with two or more lesions (39.2%, n=169). For 95 patients 8 
the number of lesions was not documented. We found indeed that 19% of the 9 
patients with more than one lesions underwent gross total or subtotal resection in 10 
contrast to 31% of the patients with only one lesion (p=0.005). Moreover, the number 11 
of lesions was indeed a prognostic factor (PFS: HR=1.40, 95% CI 1.13-1.73, p=0.002, 12 
OS: HR=1.40, 95% CI 1.11-1.77, p=0.005). However, after adjustment for the 13 
number of lesions, the HR of biopsy versus subtotal or gross total resection remained 14 
unchanged for PFS (HR=1.39, 95% CI 1.08-1.79, p=0.012) and was only slightly 15 
smaller for OS (HR=1.27, 95% CI 0.97-1.67, p=0.085). Comparable results were 16 
obtained when the number of lesions was used as a continuous covariate or when 17 
patients with one or two lesions were compared to patients with at least three lesions. 18 
The localization of lesions (supratentorial, cortical, subcortical, spinal, 19 
cerebellar/brainstem) was not associated with OS or PFS (data not shown).  20 
 21 
22 
Discussion 1 
 2 
This analysis of the largest PCNSL trial ever performed challenges the traditional 3 
view that the extent of resection has no prognostic impact in this disease and that 4 
efforts at resection should therefore be avoided. We observed that gross totally or 5 
subtotally resected patients appeared to derive a benefit from surgery (Figure). 6 
Neither differences in age nor in postoperative KPS accounted for these differences 7 
in outcome (Table). The impact of extent of resection was similar for PFS, but less 8 
prominent for OS when adjusted for the number of lesions. However, the benefit from 9 
surgery did not become apparent in the negatively selected population of 115 10 
patients from the primary eligibility population who started HD-MTX-based 11 
chemotherapy, but did not enter into the second phase of the study. This raises the 12 
possibility that there is a subpopulation of patients with aggressive, treatment-13 
resistant tumors where cytoreductive surgery does not result in improved outcome. 14 
Limitations of this analysis, which was not planned in the study protocol, include the 15 
retrospective nature and the lack of a central review of neuroimaging for extent of 16 
resection. Yet, the determination of the extent of resection was among the 17 
prospectively collected, prespecified parameters of study documentation. Moreover, 18 
pooling of gross total and subtotal resections avoids the problem of not having 19 
performed a central review of early postoperative scans to assess extent of resection.  20 
The determination of KPS after surgery might also be a limitation since patients may 21 
have an improved KPS after gross total or subtotal resection, supported by the use of 22 
steroids. It remains possible that low preoperative KPS values dissuaded surgeons 23 
from performing resections and that this bias enriched the group of biopsied patients 24 
somewhat for poor KPS. Yet, the postoperative KPS was similar and apparently 25 
independent of type of surgery (Table), indicating that such biases were not 1 
introduced to a relevant extent. 2 
The largest previous analysis of biopsy versus subtotal versus gross total resection 3 
which indicated inferior outcome at least with subtotal resection may no longer be 4 
appropriate to estimate the safety and efficacy since neurosurgery has developed 5 
and standards of adjuvant therapy have dramatically changed, too, since these 6 
patients were treated.3 Accordingly, given that no prospective study to look at the role 7 
of surgery in isolation will ever be performed, we propose to reconsider the statement 8 
that efforts at resection should be discouraged at least if resection seems safe, e.g., 9 
often in patients with single lesions, and (ii) that extent of resection should be 10 
considered for stratification or at least be assessed in future PCNSL trials. 11 
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Figure 17 
PFS (A) and OS (B) by extent of resection: gross total resection versus subtotal 18 
resection versus biopsy in the primary eligibility population of 526 patients (PFS: 19 
p=0.005 for biopsy versus gross or subtotal resection, p=0.023 for gross total versus 20 
subtotal resection; OS: p=0.024 for biopsy versus gross or subtotal resection, 21 
p=0.218 for gross total versus subtotal resection; see also Table). 22 
Table 
 Gross total 
resection 
Subtotal resection Biopsy 
N patients (%) 67 (13%) 70 (14%) 379 (73%) 
Median age (range) 63 years (19-80) 62 years (22-79) 63 years (19-84) 
Number of lesions: 
N=1 
N>1 
No data 
 
43 (64.2%) 
7 (10.4%) 
17 (25.4%) 
 
37 (52.8%) 
24 (34.3%) 
9 (12.9%) 
 
176 (46.5%) 
137 (36.1%) 
66 (17.4%) 
Median KPS (range)4 80 (30-100) 80 (30-100) 70 (20-100) 
Complete remission rate at 6 
months 
38/67 (56.7%) 29/70 (41.4%) 130/379 (34.3%) 
  OR=0.54, 95% CI 0.27-1.06, 
p=0.0741 
OR=0.40, 95% CI 0.24-0.68, 
p<0.001 1 
OR=0.74, 95% CI 0.44-1.24, 
p=0.252 2 
OR=0.55, 95% CI 0.37-0.81, 
p=0.003 3 
Median PFS (95% CI) 11 months (5-18) 15 months (0-31) 6 months (4-8) 
PFS events (%) 48/67 (72%) 49/70 (70%) 317/379 (84%) 
  HR=0.97, 95% CI 0.65-1.44, 
p=0.871 
HR=1.35, 95% CI 0.99-1.83, 
p=0.0531 
HR=1.42, 95% CI 1.05-1.91, 
p=0.0232 
HR=1.39, 95% CI 1.10-1.74, 
p=0.0053 
Median OS (95% CI) 32 months (18-46) 31 months (21-40) 18 months (14-23) 
OS events (%) 39/67 (58%) 44/70 (63%) 268/379 (71%) 
  HR=1.26, 95% CI 0.81-1.96, 
p=0.2971 
HR=1.44, 95% CI 1.03-2.02, 
p=0.0321 
HR=1.22, 95% CI 0.89-1.68, 
p=0.2182 
HR=1.33, 95% CI 1.04-1.70, 
p=0.0243 
1versus gross total resection 
2versus subtotal resection 
3versus subtotal and gross total resections pooled 
4at study entry, that is, after surgery 
partial resection  
complete resection
biopsy  
partial resection  
complete resection
biopsy  
